参附注射液联合低分子肝素在慢性肺源性心脏病重症患者中应用体会.docVIP

参附注射液联合低分子肝素在慢性肺源性心脏病重症患者中应用体会 　　【摘要】 目的：探?参附注射液联合低分子肝素应用于慢性肺源性心脏病重症患者中的疗效。方法：临床纳入2015年1月-2017年9月本院收治的72例慢性肺源性心脏病重症患者作为研究对象，根据不同治疗方案分为治疗组与对照组。其中治疗组32例，对照组40例。对照组给予氧疗、控制感染、改善心肺功能、祛痰止咳、保持气道通畅等常规治疗，治疗组在常规治疗基础上应用参附注射液联合低分子肝素进行治疗。将两组临床总有效率、治疗前后血气分析相关指标及血液流变学变化情况、用药后不良反应发生率分别进行对比。结果：治疗组临床总有效率为96.88%，显著高于对照组的77.50%（ 字2=4.078，P=0.043）。治疗组与对照组治疗前血气分析相关指标比较，差异无统计学意义（P0.05）。治疗后治疗组的pH值、PO2、PCO2等指标与对照组比较，差异均有统计学意义（P0.05）。治疗后治疗组的全血黏度、血浆黏度、红细胞比容、血小板黏附率、纤维蛋白原等指标与对照组比较，差异均有统计学意义（P0.05）。结论：在慢性肺源性心脏病常规治疗基础上采用参附注射液静点联合低分子肝素皮下注射治疗，可弥补重症慢性肺源性心脏病常规治疗方案的不足，更好地解决重症慢性肺源性心脏病患者阳气虚脱病症及血液高黏滞状态难题。故此方法在提高慢性肺源性心脏病重症患者生活质量、改善预后方面具有更好的临床效果。 　　【关键词】 参附注射液； 低分子肝素； 慢性肺源性心脏病 　　【Abstract】 Objective：To explore the effect of Shenfu Injection combined with Low Molecular Weight Heparin in patients with chronic pulmonary heart disease.Method：A total of 72 cases with chronic pulmonary heart disease in our hospital from January 2015 to September 2017，according to the different treatments they were randomly divided into treatment group and control group.The treatment group had 32 cases，the control group had 40 cases.The control group was given oxygen cure，infection control，improve cardiopulmonary function，resolve phlegm to relive cough，maintain airway patency such as conventional treatment.The treatment group on the basis of conventional treatment was given Low Molecular Weight Heparin combined with Shenfu Injection.Clinical total effective rate，blood gas analysis before and after treatment，changes related indexes and blood rheology before and after the treatment，drug adverse reaction rate of two groups were compared respectively.Result：The total clinical efficiency of the treatment group was 96.88%，significantly higher than 77.50% of the control group（ 字2=4.078，P=0.043）.There was no significant difference between two groups of blood gas analysis before the treatment（P0.05）.The comparison of pH value，PO2，PCO2 and other indicators in the treatment group and the control group after the treatment were statistica